WASHINGTON, June 15, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S.Food and Drug Administration (FDA) has granted three years of marketing exclusivity for the changes related to the supplemental New Drug Application (sNDA) that was recently approved by FDA. On May 26, 2016, Vanda announced
The FDA added this entry to the Fanapt® Orange Book listing providing exclusivity until May 26, 2019 based upon three years from the sNDA approval date.
About Vanda Pharmaceuticals Inc. Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda, please visit www.vandapharma.com.
Corporate Contact:Jim KellySenior Vice President and Chief Financial Officer Vanda Pharmaceuticals Inc. (202) [email protected]
Media Contact: Alexandra Peterson Senior Vice President, Health Practice LeaderMakovsky (212) 508-9709 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-grants-fanapt-three-years-of-marketing-exclusivity-for-labeling-changes-relating-to-maintenance-treatment-of-schizophrenia-300284868.html
SOURCE Vanda Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All